Compare OCG & DCOY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OCG | DCOY |
|---|---|---|
| Founded | 2018 | N/A |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3M | 3.2M |
| IPO Year | 2019 | 2014 |
| Metric | OCG | DCOY |
|---|---|---|
| Price | $1.59 | $2.75 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $30.00 |
| AVG Volume (30 Days) | ★ 62.8K | 18.8K |
| Earning Date | 05-14-2026 | 05-16-2026 |
| Dividend Yield | ★ 8.57% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.01 | $0.53 |
| 52 Week High | $19.29 | $13.51 |
| Indicator | OCG | DCOY |
|---|---|---|
| Relative Strength Index (RSI) | 42.08 | 31.14 |
| Support Level | $1.45 | $0.61 |
| Resistance Level | $1.88 | $3.29 |
| Average True Range (ATR) | 0.12 | 0.20 |
| MACD | -0.01 | 0.04 |
| Stochastic Oscillator | 2.50 | 12.50 |
Oriental Culture Holding Ltd is an online provider of collectibles and artwork e-commerce services. The company also offers online and offline integrated marketing, storage, and technical maintenance services to customers. The company operates through one segment, namely, e-commerce of artwork trading. The company generates revenue through listing service fees, transaction fees, and other revenues collected from traders.
Decoy Therapeutics Inc is a pre-clinical stage biotechnology company focused on advancing its pipeline of peptide conjugate therapeutics engineered through its proprietary IMP3ACT platform. The IMP3ACT platform represents a paradigm shift in peptide conjugate drug discovery and manufacturing, leveraging machine learning (ML) and artificial intelligence (AI" tools alongside high-speed synthesis techniques to rapidly engineer, optimize and manufacture peptide conjugates that target serious unmet medical needs. The company manages its business in one operating segment, focused on the discovery and development therapeutics for patients with high, unmet medical needs. Its pipeline programs include: Pan-Coronavirus; and Tripledemic.